Candel Therapeutics (CADL)
US Market

Candel Therapeutics (CADL) Income Statement


Candel Therapeutics Income Statement

Last quarter (Q2 2023), Candel Therapeutics's total revenue was $―, a decrease of -100.00% from the same quarter last year. In Q2, Candel Therapeutics's net income was $-9.61M. See Candel Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 38.00K$ 100.00K$ 125.00K$ 125.00K$ 125.00K
Cost of Revenue
Gross Profit
$ 7.00K$ 100.00K---
Operating Expense
$ 19.99M$ -34.85M$ 24.77M$ 13.31M$ 8.59M
Operating Income
$ -36.22M$ -34.75M$ -24.65M$ -13.19M$ -8.47M
Net Non Operating Interest Income Expense
$ -141.00K$ -490.00K$ -53.00K$ 111.00K$ 1.07M
Other Income Expense
$ -3.32M$ -16.42M$ -11.42M$ -4.61M$ -844.00K
Pretax Income
$ -32.20M$ -18.82M$ -36.12M$ -17.68M$ -8.24M
Tax Provision
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -32.20M$ -18.82M$ -36.12M$ -17.68M$ -8.24M
Basic EPS
$ -1.14$ -0.65$ -1.91$ -0.95$ -0.44
Diluted EPS
$ -1.11$ -0.65$ -1.91$ -0.95$ -0.44
Basic Average Shares
$ 115.56M$ 28.82M$ 18.87M$ 18.68M$ 18.68M
Diluted Average Shares
$ 115.56M$ 28.82M$ 18.87M$ 18.68M$ 18.68M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
--$ 250.00K$ 256.00K$ 204.00K
Total Expenses
$ 19.99M$ -34.85M$ 24.77M$ 13.31M$ 8.59M
Net Income From Continuing And Discontinued Operation
$ -32.20M$ -18.82M$ -36.12M$ -17.68M$ -8.24M
Normalized Income
$ -16.65M-$ -24.70M$ -13.07M$ -8.24M
Interest Expense
--$ 53.00K--
$ -32.08M$ -18.33M$ -36.07M$ -13.19M$ -8.47M
$ -23.35M$ -19.13M$ -35.84M$ -13.10M$ -8.42M
Currency in USD

Candel Therapeutics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis